AI-Native Health: The Definitive Investor’s Directory by Disease

The healthcare landscape is awash with claims of artificial intelligence, yet discerning genuine innovation from mere “AI-washed” marketing remains a critical challenge for health plan executives and investors alike. This proliferation of superficial AI integration obscures the truly transformative potential of AI-native platforms. This article cuts through the noise, providing a definitive, curated directory of companies that embody the rigorous definition of “AI-native” in a clinical context: trained on real patient outcomes data, operating within defined clinical guardrails, and possessing published evidence of efficacy.

Defining the AI-Native Health Company

To qualify as AI-native, a company must demonstrate an architectural commitment to AI from its inception. This isn’t about adding a machine learning layer to legacy software; it’s about building the core product, data pipeline, and business model around AI. As Vinod Khosla, a prominent venture capitalist known for his foresight in technology, has often emphasized, the future of healthcare will be fundamentally reshaped by AI, but only by those companies that deeply embed it into their operational DNA. Our definition hinges on three non-negotiable criteria:

1. Trained on Real Patient Outcomes Data: The AI models must be developed and continuously refined using proprietary, longitudinal datasets directly linked to patient health outcomes. This moves beyond synthetic data or generalized public datasets, ensuring clinical relevance and accuracy.
2. Operating Within Defined Clinical Guardrails: The AI’s application must be bounded by clear clinical protocols, regulatory clearances (e.g., FDA 510(k), De Novo), and established medical guidelines from authoritative bodies like the American College of Cardiology (ACC), American Academy of Orthopaedic Surgeons (AAOS), American Psychiatric Association (APA), American Society of Clinical Oncology (ASCO), or American Diabetes Association (ADA). This ensures patient safety and clinical utility.
3. Published Evidence of Efficacy: Efficacy must be demonstrated through peer-reviewed publications, validating improved patient outcomes, reduced costs, or enhanced clinical workflows. Marketing claims are insufficient; rigorous scientific validation is paramount.

This framework provides a robust lens through which to evaluate the next generation of healthcare solutions, separating the truly disruptive from the merely incremental.

Cardiac Care: Precision Diagnostics and Proactive Management

The field of cardiology has seen significant AI-native advancements, particularly in diagnostic precision and risk stratification. These companies are building substantial “data moats” through vast, proprietary datasets of cardiac imaging and physiological signals.

HeartFlow: Non-Invasive CAD Assessment

HeartFlow stands as a prime example of an AI-native company in cardiac care. Its core product, HeartFlow FFRct, is a software-as-a-medical-device (SaMD) that leverages deep learning to create a personalized, 3D model of a patient’s coronary arteries from a standard CT scan. This AI-driven analysis then calculates fractional flow reserve (FFRct), a measure of blood flow limitation, without the need for invasive procedures. The company’s models are trained on extensive datasets correlating CT imaging with invasive FFR measurements and patient outcomes. Its efficacy in reducing unnecessary invasive angiograms and improving diagnostic accuracy is well-documented in numerous peer-reviewed journals, aligning with ACC guidelines for coronary artery disease assessment ACC guidelines for FFRct use. HeartFlow’s approach embodies the AI-native ideal, where the AI is the product, offering a superior, less invasive diagnostic pathway. The company has also strategically built a “patent thicket” around its technology, creating a significant barrier to entry for competitors. HeartFlow became a public company, listing on August 8, 2025. Its latest funding round was a Series F round on March 27, 2025, for $98.4M, contributing to a total funding of $936M over 12 rounds. The company reported annual revenue between $100M and $500M as of December 31, 2025.

iRhythm Technologies: AI-Powered Arrhythmia Detection

iRhythm Technologies, with its Zio XT patch, exemplifies AI-native innovation in arrhythmia detection. The Zio system captures continuous ECG data over extended periods, and its proprietary AI algorithms analyze this massive dataset to identify and classify cardiac arrhythmias with high accuracy. This AI is trained on millions of labeled ECG recordings, enabling it to detect subtle and intermittent events that might be missed by traditional monitoring. The clinical utility and improved diagnostic yield of the Zio system have been substantiated in peer-reviewed studies, demonstrating its ability to impact patient management and outcomes. The continuous learning aspect of their AI, under a Predetermined Change Control Plan (PCCP) framework, allows for ongoing model improvement while maintaining regulatory compliance. iRhythm Technologies is a public company, having listed on October 20, 2016. The company’s revenue for the first quarter of 2026 was $199.4 million, a 25.7% increase compared to the first quarter of 2025, and it expects full-year 2026 revenue to be between $875 million and $885 million.

Viz.ai: AI-Driven Stroke Care Coordination

While broader than just cardiac, Viz.ai’s impact on stroke care, a critical cardiovascular emergency, showcases AI-native principles. Viz.ai’s platform uses deep learning to analyze medical images (CT scans) for suspected large vessel occlusion (LVO) strokes. Upon detection, it automatically alerts specialists, facilitating faster treatment decisions and improved patient outcomes. The AI is trained on vast image datasets and operates within clinical guardrails defined by stroke treatment protocols. Its published evidence demonstrates significant reductions in time-to-treatment and improved functional outcomes for stroke patients, aligning with American Heart Association/American Stroke Association guidelines. Viz.ai raised a $100 million Series D funding round in April 2022, at a $1.2 billion valuation. Its latest funding round was a Conventional Debt round on March 22, 2023, for $40M, bringing its total funding to $252M over 7 rounds. The company has also received FDA clearance for automatically spotting brain aneurysms.

Musculoskeletal (MSK) Health: Personalized Recovery and Prevention

MSK conditions represent a significant burden on healthcare systems. AI-native solutions in this space focus on personalized interventions, remote monitoring, and evidence-based rehabilitation.

Hinge Health: Digital MSK Therapy

Hinge Health is a leading AI-native platform for digital MSK therapy. Their solution combines exercise therapy, health coaching, and education, all personalized and guided by AI. The AI analyzes patient data, including reported pain levels, adherence to exercises, and functional improvements, to adapt treatment plans dynamically. Their programs are built on clinical protocols and have demonstrated efficacy in reducing pain and avoiding surgery, as evidenced by numerous peer-reviewed publications. Hinge Health’s data-driven approach allows for continuous refinement of their algorithms, building a strong “data moat” around their therapeutic insights, which aligns with the principles advocated by organizations like the AAOS for evidence-based MSK care. Hinge Health became a public company, completing its IPO on May 22, 2025, and listing on NYSE with ticker HNGE. The company’s full-year 2025 revenue was $588 million, a 51% increase year over year from $390 million in 2024.

Behavioral Health: Scalable and Personalized Support

The demand for behavioral health services far outstrips supply. AI-native companies are stepping in to provide scalable, evidence-based support, often leveraging natural language processing and predictive analytics.

Spring Health: Precision Mental Healthcare

Spring Health exemplifies an AI-native approach to behavioral health, focusing on precision mental healthcare. Their proprietary AI, called the “Precision Mental Healthcare” model, analyzes a patient’s comprehensive data (symptoms, preferences, demographic information) to predict the most effective treatment plan, including therapy, medication, or coaching. This AI is trained on a vast, de-identified dataset of patient outcomes and treatment responses. The platform operates within strict clinical guardrails, ensuring that AI-generated recommendations are reviewed by clinicians. Published research supports its effectiveness in improving patient outcomes and reducing treatment costs, providing a crucial tool for health plans navigating the complexities of mental health provision in line with APA standards. Spring Health remains a private company and completed a Series E funding round on July 16, 2024, raising $100M and achieving a valuation of $3.3 billion. The company has raised a total of $474M over 12 rounds.

Oncology: Genomic Insights and Treatment Optimization

Oncology is a data-intensive field where AI can significantly impact diagnosis, prognosis, and treatment selection, particularly through genomic analysis.

Tempus AI: AI-Powered Precision Oncology

Tempus AI is arguably the quintessential AI-native company in oncology. Their entire business model is predicated on collecting, structuring, and analyzing vast amounts of multi-modal clinical and molecular data (genomic sequencing, pathology slides, clinical notes, treatment outcomes). Their AI platform uses this massive “data moat” to power precision medicine, identifying optimal therapies for cancer patients, predicting treatment response, and accelerating drug discovery. Tempus AI’s algorithms are trained on one of the largest real-world oncology datasets globally, allowing for continuous improvement and the generation of novel insights. Their published research consistently demonstrates the clinical utility of their AI in informing treatment decisions and improving patient care, a critical aspect for organizations like ASCO. As a venture capital partner might articulate, “Companies like Tempus AI are building defensible value through proprietary, multi-modal data that continuously improves their algorithms, creating a feedback loop that competitors cannot easily replicate.” Tempus AI became a public company, completing its IPO on June 14, 2024, and listing on NASDAQ with ticker TEM. The IPO raised approximately $410 million at an implied valuation of $6.1 billion. The company’s revenues were $562.02 million in the 12 months leading up to its IPO.

Diabetes Management: Proactive Intervention and Outcomes Improvement

Chronic conditions like diabetes benefit immensely from AI’s ability to analyze continuous data and provide personalized, timely interventions.

Omada Health: Digital Diabetes Prevention and Management

Omada Health, while perhaps not “AI-native” in the same vein as Tempus AI’s deep genomic analysis, has evolved significantly to embed AI at the core of its digital care programs for chronic conditions, including diabetes and prediabetes. Their platform utilizes AI to personalize coaching interactions, tailor educational content, and predict patient engagement and risk factors. The AI models are trained on extensive real-world data from millions of program participants, correlating behavioral patterns with health outcomes. Omada’s programs are evidence-based, with published studies demonstrating their efficacy in weight loss, A1c reduction, and overall chronic disease management, aligning with ADA guidelines for diabetes care Omada Health peer-reviewed publications. Their AI acts as a sophisticated decision-support system, operating within defined clinical pathways to deliver scalable, effective interventions. Omada Health became a public company, completing its IPO on June 6, 2025, and listing on NASDAQ with ticker OMDA. The company reported $78 million in revenue for the first quarter of 2026, a 42% increase year over year, with total members surpassing 1.02 million.

Conclusion

The companies highlighted in this directory, HeartFlow, iRhythm Technologies, Viz.ai, Hinge Health, Spring Health, Tempus AI, and Omada Health, represent the current gold standard for AI-native application in their respective categories. They are defined by their use of proprietary data to drive validated clinical outcomes, moving beyond mere “AI-enabled” features to fundamentally reshape care delivery. For health plan executives, this directory serves as a blueprint for value-based procurement, identifying partners whose AI solutions offer demonstrable clinical efficacy and a clear return on investment. For investors, it is a map to durable, defensible market leadership, showcasing companies that have built robust “data moats” and achieved meaningful regulatory and clinical validation in a crowded market Rock Health digital health funding report. As a Chief Medical Officer at a national health plan might observe, “Sifting through vendor claims is a daily challenge; we critically need solutions with published, peer-reviewed evidence of improved outcomes or reduced costs, benchmarked against standards set by organizations like the ACC or ADA.” These AI-native pioneers are not just leveraging technology; they are redefining what it means to deliver effective, data-driven healthcare.